Acquisitions (Tables) - Preomics Gmbh [Member]

3 Months Ended

Mar. 31, 2022

Acquisitions

Schedule of Components and Fair Value Allocation of the Consideration Transferred in Connection with Acquisitions

The components and fair value allocation of the consideration transferred in connection with the acquisition are as follows (in millions):

Consideration Transferred:
Cash paid	$	52.1
Cash acquired		(16.0	)
Fair value of hybrid financial instrument - founders		20.9
Fair value of redeemable noncontrolling interest - other shareholders		6.8
Total consideration transferred	$	63.8
Allocation of Consideration Transferred:
Accounts receivable	$	0.4
Inventories		0.6
Other current assets		0.7
Property, plant and equipment		1.3
Other assets		0.4
Intangible assets:
Technology		12.5
Customer relationships		6.9
Trade name		1.9
Goodwill		47.0
Liabilities assumed		(7.9	)
Total consideration allocated	$	63.8

Schedule of Consideration Transferred and the Respective Reporting Segment for Each Acquisition

The following table reflects the consideration transferred and the respective reporting segment for the acquisitions (in millions):

Name of Acquisition	Date Acquired	Segment	Total Consideration		Cash Consideration
Prolab Instruments GmbH	January 17, 2022	BSI Life Science	$	5.7	$	5.5
PepSep Holding ApS	February 1, 2022	BSI Life Science		4.1		2.8
			$	9.8	$	8.3

In the three months ended March 31, 2022, the Company completed a minority investment that complemented the Company's existing product offerings. The following table reflects the consideration transferred and the respective reporting segment for this investment (in millions):

Name	Acquisition / Investment	Date Acquired	Segment	Total Consideration		Cash Consideration
PrognomiQ, Inc	Investment	February 16, 2022	BSI Life Science	$	12.0	$	12.0
				$	12.0	$	12.0